AIM ImmunoTech Shares Jump 42% After Pancreatic Cancer Trial Enrollment Milestone
AZN•AIM ImmunoTech shares jumped 42% after completing enrollment in its Phase 2 trial of Ampligen plus Imfinzi for metastatic pancreatic cancer ahead of schedule. The company targets Clinical Benefit Rate by December 2026, plans to complete dosing this year and is advancing Phase 3 plans with US and European orphan drug designations.
1. Enrollment Milestone Spurs Stock Rally
The company completed final patient enrollment in its Phase 2 Ampligen plus Imfinzi trial for metastatic pancreatic cancer ahead of schedule, driving shares up 42%. The accelerated enrollment highlights robust trial execution and heightened investor interest.
2. Trial Progress and Endpoint Timelines
Management stated dosing is on track for completion this year, with the primary endpoint of Clinical Benefit Rate slated for evaluation in December 2026. CBR will measure the percentage of patients achieving disease stability or response six months after treatment initiation.
3. Orphan Designations and IP Expansion
The company has secured orphan drug designations for Ampligen in both the US and Europe, enhancing regulatory incentives and market exclusivity. Concurrently, it is expanding its global intellectual property portfolio to support late-stage development.
4. Phase 3 Planning and Clinical Data
Phase 3 trial planning is underway, leveraging data from a Dutch Named Patient Program and the ongoing DURIPANC study. More than 100 pancreatic cancer patients have received Ampligen across programs, building a robust clinical experience base for the forthcoming late-stage trial.
